Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 3;48(2):112-132.
doi: 10.55730/1300-0152.2687. eCollection 2024.

Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems

Tuğba Gül Inci  1 , Serap Acar  1 , Dilek Turgut-Balik  1
Affiliations

Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems

Tuğba Gül Inci et al. Turk J Biol. .

Abstract

Drug repurposing is the strategy of drug utilization for a treatment option other than the intended indications. This strategy has witnessed increased adoption over the past decades, especially within cancer nanomedicine. Cancer nanomedicine has been facilitated through nanoparticle-based (NP-based) delivery systems which can combat nonsmall-cell lung cancer (NSCLC) via recent advances in nanotechnology and apply its benefits to existing drugs. The repurposing of drugs, coupled with NP-based drug delivery systems, presents a promising avenue for achieving effective therapeutic solutions with accelerated outcomes. This review aims to present an overview of NSCLC treatments, with a specific focus on drug repurposing. It seeks to elucidate the latest advances in clinical studies and the utilization of NP-based drug delivery systems tailored for NSCLC treatment. First, the molecular mechanisms of Food and Drug Administration (FDA)-approved drugs for NSCLC, including ROS1 tyrosine kinase inhibitors (TKI) like repotrectinib, approved in November 2023, are detailed. Further, in vitro studies employing a combination strategy of drug repurposing and NP-based drug delivery systems as a treatment approach against NSCLC are listed. It includes the latest study on nanoparticle-based drug delivery systems loaded with repurposed drugs.

Keywords: Drug repurposing; NSCLC; nanoparticle-based drug delivery systems; nonsmall-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Structure of the review.
Figure 2
Figure 2
Percentage of the approved active substances for NSCLC drugs (NIH, 2023)1
Figure 3
Figure 3
Timeline for NP-based drug delivery systems for cancer treatment. (The NP for NSCLC is indicated with bold line).
See this image and copyright information in PMC

References

    1. Akinboro O, Larkins E, Pai Scherf LH, Mathieu LN, Ren Y, et al. FDA approval summary: pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of Advanced/Metastatic PD-L1–high NSCLC. Clinical Cancer Research. 2022;28:2221–2228. doi: 10.1158/1078-0432.CCR-21-3844. - DOI - PubMed
    1. Alfaifi MY, Shati AA, Elbehairi SEI, Fahmy UA, Alhakamy NA, et al. Anti-tumor effect of PEG-coated PLGA nanoparticles of febuxostat on A549 non-small cell lung cancer cells. 3 Biotech. 2020;10:1–10. doi: 10.1007/s13205-020-2077-x. - DOI - PMC - PubMed
    1. Alhakamy NA, Md S. Repurposing itraconazole loaded PLGA nanoparticles for improved antitumor efficacy in non-small cell lung cancers. Pharmaceutics. 2019;11:685. doi: 10.3390/pharmaceutics11120685. - DOI - PMC - PubMed
    1. Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. The Oncologist. 2013;18:163–173. doi: 10.1634/theoncologist.2012-314. - DOI - PMC - PubMed
    1. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery. 2004;3:673–683. doi: 10.1038/nrd1468. - DOI - PubMed

LinkOut - more resources